Nektar Therapeutics Stock News

Morgan Stanley reduced its position in Nektar Therapeutics (NASDAQ:NKTR) by 8.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 477,014 shares of the biopharmaceutical companys stock after selling 42,117 shares during the quarter. Morgan Stanley owned 0.26% of Nektar Therapeutics []

Equities research analysts expect Nektar Therapeutics (NASDAQ:NKTR) to announce ($0.82) earnings per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Nektar Therapeutics earnings. The highest EPS estimate is ($0.74) and the lowest is ($0.89). Nektar Therapeutics posted earnings of ($0.65) per share during the same quarter last year, []

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

Nektar Therapeutics (NASDAQ:NKTR) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 1.84% to the previous days close as strong demand from buyers drove the stock to $11.62. Actively observing the price movement in the last trading, the stock closed the session at $11.41, falling within a range of $11.09 and Thinking About Buying Nektar Therapeutics Stock? Heres What You Need To Know. Read More »

Marshall Wace North America L.P. bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 33,724 shares of the biopharmaceutical companys stock, valued at approximately $579,000. A number of other large investors also recently modified their []

Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 3,000 shares of the companys stock in a transaction that occurred on Thursday, November 18th. The stock was sold at an average price of $12.69, for a total value of $38,070.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through []

Price T Rowe Associates Inc. MD reduced its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 3.4% in the second quarter, HoldingsChannel.com reports. The firm owned 513,965 shares of the biopharmaceutical companys stock after selling 18,199 shares during the period. Price T Rowe Associates Inc. MDs holdings in Nektar Therapeutics were worth $8,820,000 at the []

Nektar Therapeutics (NASDAQ:NKTR)s stock price reached a new 52-week low on Thursday . The stock traded as low as $12.17 and last traded at $12.23, with a volume of 8395 shares changing hands. The stock had previously closed at $12.85. Several equities analysts have weighed in on NKTR shares. Bank of America started coverage on []

Related Stocks: NKTR ,

Global NK Cell Therapy Market report 2021 focuses on the industry status, future forecast, growth opportunity, key market, and key players. This study is very useful information for new and growing companies to display themselves in the market. Additionally, the

Millennium Management LLC lifted its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 434.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 576,389 shares of the biopharmaceutical companys stock after buying an additional 468,486 shares during the period. Millennium Management LLC []

Wall Street analysts expect that Nektar Therapeutics (NASDAQ:NKTR) will announce earnings per share (EPS) of ($0.82) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Nektar Therapeutics earnings, with estimates ranging from ($0.89) to ($0.74). Nektar Therapeutics reported earnings of ($0.65) per share during the same quarter last year, []

Nektar Therapeutics (NASDAQ:NKTR) price closed lower on Friday, November 12, dropping -1.40% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Charles Schwab Investment Management Inc. increased its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 2.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 891,265 shares of the biopharmaceutical companys stock after buying an additional 19,850 shares during the quarter. Charles []

Friday, November 5th's trading of NKTR (NKTR) was - in our opinion - a short/manipulator shakedown of epic proportions. Nektar's 3Q conference call was clumsily executed but contained strong data and